These molecular alterations suggest that LARS2 and SEZ6L2 might contribute to COAD progression by promoting tumor growth and immune evasion, whereas SOX7 downregulation may facilitate tumor development by impairing tumor suppressive pathways. This evidence concerns the gene SEZ6L2 and neoplasm.